ATS 2019 Virtual Final Program

This symposium aims to provide new insights into the interactions between the signaling pathways determining the fate of resident and itinerant progenitor cells in the lung and how signals from the microenvironments in the vascular, epithelial, and mesenchymal compartments shape cell fate. The origins and plasticity of alveolar type I and type II cells will be explored. The session will also focus on the parallels between developmental pathways by which progenitor cells evolve into fully differentiated cells that constitute functional lung and the pathways responsible for repair and remodeling of the injured lung in health and in conditions such as pulmonary fibrosis, pulmonary infections, ARDS, LAM, and COPD as well as key areas of research and treatment relevant to these diseases. Chairing: G.P. Downey, MD, Denver, CO B.D. Levy, MD, ATSF, Boston, MA K. Asano, MD, Kanagawa, Japan E.R. Neptune, MD, Baltimore, MD 9:15 Introduction to Development, Fate and Plasticity of Cells in the Lung Z. Borok, MD, ATSF, Los Angeles, CA 9:32 Applications of Functional Lung Epithelial Cells Derived from Human Pluripotent Stem Cells S. Gotoh, MD, PhD, Kyoto, Japan 9:49 One Cell at a Time: Dissecting Cellular and Molecular Heterogeneity of the Human Tracheal Airway Through Single Cell Transcriptomics M.A. Seibold, PhD, Denver, CO 10:06 The Vascular Niche Regulates Lung Regeneration and Fibrosis B. Ding, PhD, New York, NY 10:23 Mechanisms of Alveolar Epithelial Proliferation and Differentiation After Lung Injury R. Zemans, MD, Ann Arbor, MI 10:40 Lung Tissue Mimetic Hydrogels and Genome Engineering for Lymphangioleiomyomatosis (LAM) Modeling and Drug Development W. Stanford, PhD, Ottawa, Canada 10:57 Specialized Facultative Progenitor of the Alveolar Epithelium W. Zacharias, MD, PhD, Cincinnati, OH CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 A6 PAP FOR ALL OR PAP FOR FEW: CONTROVERSIES IN MANAGEMENT OF SLEEP-DISORDERED BREATHING Assembly on Sleep and Respiratory Neurobiology 9:15 a.m. - 11:15 a.m. KBHCCD Room C155-C156 (Level 1) Target Audience Pulmonary and critical care physicians, sleep physicians, fellows in training, physician extenders, respiratory therapists Objectives At the conclusion of this session, the participant will be able to: • become aware of controversy as it relates to managing asymptomatic patients with OSA and CVD and be able to apply new knowledge competence and implement practice changes as appropriate for treatment of these patients; • gain improved ability to determine the best mode of PAP therapy (CPAP or NIV) in OHS given patient characteristics and selected outcomes; • recognize the various reasons why clinical trials in cardiovascular disease have led to negative outcomes and what changes in trial design the sleep field should aim for in the future. The goal of this scientific symposium is to debate controversial in clinical trials related to the treatment of sleep-disordered breathing using a pro/con format. Historically, these pro/con debates have been lively, well-attended, and allow discussion of a broad range of topics within a single symposium. We include topics in which recent studies have informed clinical care, but where management decisions are still not entirely clear and guidelines are not in place incorporating new data. Experts from around the globe have been recruited for this symposium. Specifically, we will debate the following topics: 1) whether treatment of OSA leads to any improvement in cardiovascular outcomes, 2) What are potential reasons for negative PAP trials in heart failure, and what future therapies and designs should be considered in this population, and 3) whether obesity hypoventilation syndrome should be treated with CPAP or NIV and the impact of these treatment modalities on cardiovascular outcomes. Finally, Dr. Robert Wise, who has extensive trial experience and involvement in landmark trials in Pulmonary and Critical Care, will offer a unique and instructive “outside perspective” on what direction SDB trials should take in the future. Chairing: S. Pamidi, MD, Montreal, Canada N.A. Shah, MD, MPH, MSci, New York, NY S.R. Patel, MD, Pittsburgh, PA B. Mokhlesi, MD, MSc, Chicago, IL 9:15 Introduction B. Mokhlesi, MD, MSc, Chicago, IL 9:20 PRO: Moderate to Severe OSA Should Be Treated to Improve Cardiovascular Outcomes S.S. Redline, MD, Boston, MA 9:35 CON: Moderate to Severe OSA Should NOT Be Treated to Improve Cardiovascular Outcomes R.D. McEvoy, MD, MBBS, Adelaide, Australia 9:50 PRO: Treatment of Ambulatory Patients with Obesity Hypoventilation Syndrome (OHS) Should Start with CPAP A.J. Piper, MEd, PhD, Camperdown, Australia 10:05 CON: Treatment of Ambulatory Patients with OHS Should Start with Noninvasive Ventilation (NIV) P.B. Murphy, MBBS, PhD, London, United Kingdom 10:20 PRO: PAP Therapy Should Be Used in Patients with Central Sleep Apnea and Heart Failure M.T. Naughton, MD, ATSF, Prahran, Australia 10:35 CON: PAP Therapy Should NOT Be Used in Patients with Central Sleep Apnea and Heart Failure A. Malhotra, MD, ATSF, La Jolla, CA 10:50 Clinical Trials in Sleep-Disordered Breathing: An Outsider’s Perspective R.A. Wise, MD, Baltimore, MD ATS 2019 • Dallas, TX SUNDAY • MAY 19 27 SUNDAY MORNING